Aditxt CEO Amro Albanna hosted a stakeholder Q&A session on October 11, 2024, addressing key concerns and outlining the company's strategic direction. The CEO clarified that Aditxt is not facing immediate NASDAQ delisting risk and confirmed the current outstanding share count at 4.7 million. He emphasized that Monday's prospectus supplement filing was not a new equity line but a shift of an existing agreement to the S3.The company is focusing on three core areas: business development through Adimune™, Pearsanta™ programs and potential acquisitions of Appili and Evofem; addressing cap table overhang including preferred shares and debt; and ensuring efficient capital access for growth. The CEO highlighted plans for commercial launches in 2025, including prostate cancer and endometriosis treatments.Albanna outlined Aditxt's vision to transition from a speculative company in 2024 to one with strong fundamentals in 2025, emphasizing their focus on innovative health solutions across multiple sectors including cancer diagnostics, immune system treatments, infectious diseases, and women's health. The company committed to maintaining regular stakeholder communications and transparency regarding challenges and progress.

Aditxt CEO Amro Albanna hosted a stakeholder Q&A session on October 11, 2024, addressing key concerns and outlining the company's strategic direction. The CEO clarified that Aditxt is not facing immediate NASDAQ delisting risk and confirmed the current outstanding share count at 4.7 million. He emphasized that Monday's prospectus supplement filing was not a new equity line but a shift of an existing agreement to the S3.The company is focusing on three core areas: business development through Adimune™, Pearsanta™ programs and potential acquisitions of Appili and Evofem; addressing cap table overhang including preferred shares and debt; and ensuring efficient capital access for growth. The CEO highlighted plans for commercial launches in 2025, including prostate cancer and endometriosis treatments.Albanna outlined Aditxt's vision to transition from a speculative company in 2024 to one with strong fundamentals in 2025, emphasizing their focus on innovative health solutions across multiple sectors including cancer diagnostics, immune system treatments, infectious diseases, and women's health. The company committed to maintaining regular stakeholder communications and transparency regarding challenges and progress.